Clinical studies recruiting near Erlangen

Studies with at least one listed site matching this location on the public registry. Each page explains the study in plain language, with locations and study-team contacts. Clinicians: generate a printable list for your patient →

A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
Phase 3 · Universitaetsklinikum Erlangen · Eli Lilly and Company · NCT07218380 Recombinant Factor VIIa (rFVIIa) for Hemorrhagic Stroke Trial - Part 2
Phase 3 · University Hospital Erlangen · Joseph Broderick, MD · NCT07227246 Interfant-21 Treatment Protocol for Infants Under 1 Year With KMT2A-rearranged ALL or Mixed Phenotype Acute Leukemia
Phase 3 · Universitaetsklinikum Erlangen AöR · Princess Maxima Center for Pediatric Oncology · NCT05327894 Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
Phase 3 · Universitaetsklinikum Erlangen-Klinik für Gynäkologie und Ge · Merck Sharp & Dohme LLC · NCT06393374 Real-world Experience Using Nemolizumab in the Treatment of Moderate-to-Severe Atopic Dermatitis in Adolescents & Adults
Phase N/A · Galderma Investigational Site 6369 · Galderma R&D · NCT06988605 Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients
Phase 2 · Klinikum Erlangen der Friedrich-Alexander-Universitaet Erlan · Miltenyi Biomedicine GmbH · NCT04844866 Transfer Effects of Stationary Bicycle Perturbation Training on Older Adults' Cycling Skills
NA · University of Erlangen-Nürnberg Medical School · NCT06453473 A 52-week Study of Rilzabrutinib Efficacy and Safety Compared to Placebo in Adults Diagnosed With IgG4-related Disease
Phase 3 · Investigational Site Number : 2760003 · Sanofi · NCT07190196 Randomization of Single vs Multiple Arterial Grafts
NA · University Hospital Erlangen · Weill Medical College of Cornell University · NCT03217006 The Oxford Risk Factors And Non-Invasive Imaging Study
Phase N/A · Friedrich-Alexander-Universitat Erlangen-Nurmberg · University of Oxford · NCT05169333 Immune Biomarkers in Prostate Cancer Patients Treated With Brachytherapy
Phase N/A · Strahlenklinik Erlangen · University of Erlangen-Nürnberg Medical School · NCT07131956 MSOT and MRI for Non-invasive Assessment of Intestinal Transit Time in Children With Chronic Bowel Emptying Disorders
NA · University Hospital Erlangen, Pediatric Surgery · Dr. med. Sonja Diez · NCT06911749 A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease
Phase 3 · Universitatsklinikum Erlangen · Janssen Research & Development, LLC · NCT07499232 DEfeating PEnile CAncer-2
NA · Universitätsklinikum Erlangen · University Hospital Tuebingen · NCT07378670 International HIT-MED Registry (I-HIT-MED)
Phase N/A · University Hospital Erlangen · Universitätsklinikum Hamburg-Eppendorf · NCT02417324 A Study to Understand How the Study Medicine (PF-06823859) Works in People With Active Idiopathic Inflammatory Myopathie
Phase 3 · Universitaetsklinikum Erlangen · Pfizer · NCT05895786 Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Seve
Phase N/A · Universitätsklinikum Erlangen Kinder- und Jugendklinik · Esteve Pharmaceuticals, S.A. · NCT00903110 Effects of Intermittent Fasting and Exercise on Inflammation, Metabolism, and the Microbiome in Metabolic Syndrome
NA · Hector-Center for Nutrition, Exercise and Sports, University · University of Erlangen-Nürnberg Medical School · NCT06885255 PROOFS-Registry - Premenopausal Women With Breast Cancer Optimally Treated With OFS
Phase N/A · Universitätsklinikum Erlangen · Women's Cancer Study Group GmbH · NCT05792150 GMALL Registry and Collection of Biomaterial: Prospective Data Collection Regarding Diagnosis, Treatment and Outcome of
Phase N/A · Universitätsklinikum Erlangen · Goethe University · NCT02872987 MB-CART19.1 in Refractory SLE
Phase 1/Phase 2 · Universitätsklinikum Erlangen, Medizinische Klinik 3 · Miltenyi Biomedicine GmbH · NCT06189157 Genomics Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast Cancer (COGNITION-GUIDE)
Phase 2 · Universitätsklinikum Erlangen · German Cancer Research Center · NCT05332561 A Study of LY4257496 in Participants With Cancer (OMNIRAY)
Phase 1 · Universitaetsklinikum Erlangen · Eli Lilly and Company · NCT07114601 Prospective Evaluation of Univentricular Hearts
NA · Universitätsklinikum · University of Erlangen-Nürnberg Medical School · NCT05620030 Post-Marketing Surveillance of Vliwazell® Prowound Dressing
Phase N/A · Hautklinik · Lohmann & Rauscher · NCT07316556 Long-Term Follow-up of Patients Treated With Miltenyi Cell and Gene Therapies
NA · Uniklinikum Erlangen · Miltenyi Biomedicine GmbH · NCT06508775 The DefiPace Study
Phase N/A · Universitätsklinikum Erlangen · Institut für Pharmakologie und Präventive Medizin · NCT04804748 A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes
Phase N/A · Local Institution - 0101 · Bristol-Myers Squibb · NCT05489705 Long-term Efficacy, Safety and Tolerability of Iptacopan in C3G or IC-MPGN
Phase 3 · Novartis Investigative Site · Novartis Pharmaceuticals · NCT03955445 Real-world Experience With Lutetium Vipivotide Tetraxetan in Metastatic Castration Resistant Prostate Cancer
Phase N/A · Novartis Investigative Site · Novartis Pharmaceuticals · NCT06517719

Look up another city

Look up another condition